| 摘要 |
A purine derivative or a prodrug or salt thereof has the formula (I) wherein: X is oxy, methylene or thio; Y is CH or N; Z is H, alkyl, alkyloxy, trifluoromethyl or halo; R1 is hydroxymethyl, alkoxymethyl, cycloalkoxymethyl, carboxy, alkoxycarbonyl, cycloalkoxycarbonyl, 1,1- aminoiminomethyl, 1,1-(mono-N- or di-N,N-alkylamino)- iminomethyl, 1,1-(mono-N- or di-N,N-cycloalkylamino)- iminomethyl, carbamoyl, mono-N- or di-N,N- alkylaminocarbonyl, mono-N- or di-N,N- cycloalkylaminocarbonyl, N-alkyl-N-cycloalkylaminocarbonyl; R2 is H, alkyl or cycloalkyl; R3 is halo, trifluoromethyl, cyano, alkyl, alkyloxy, ethenyl or ethynyl; D is oxy, thio, alkyloxy, alkylthio or alkylamino; G is a optionally saturated optionally substituted 5 to 8 membered ring or a bicyclic ring consisting of two fused 3 to 6 membered rings optionally containing 1 to 4 heteroatoms selected from N, O or S or G is cyano, tetrazolyl, alkoxycarbonyl, cycloalkoxycarbonyl, C(O)NR4R5, C(S)NR4R5, C(NH)NR4R5, C(N-alkyl)-NR4R5 or C(N- cycloalkyl)NR4R5 and R4 and R5 are as defined in the specification. The compounds are useful as A-3 receptor agonists for treating ischemia or hypoxia.
|
